Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Selected Papers from the 9th International Electronic Conference on Medicinal...
share announcement

Selected Papers from the 9th International Electronic Conference on Medicinal Chemistry (ECMC2023)

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 25 May 2024 | Viewed by 458

Special Issue Editors

Dr. Alfredo Berzal-Herranz

E-Mail Website
Guest Editor
Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra (IPBLN-CSIC), PTS Granada, Av del Conocimiento 17, 18016 Granada, Spain
Interests: antiviral nucleic acids; therapeutic RNA; aptamers; RNA inhibitors; structure/function of RNA; RNA viruses
Special Issues, Collections and Topics in MDPI journals
Dr. Maria Emília De Sousa

E-Mail Website1 Website2
Guest Editor
1. Interdisciplinary Centre of Marine and Environmental Research (CIIMAR), 4450-208 Porto, Portugal
2. Laboratory of Organic and Pharmaceutical Chemistry, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
Interests: medicinal chemistry; organic synthesis; heterocycles; P-glycoprotein; anticancer; antimicrobials; chiral drugs; marine natural products
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

As indicated in the information of the 9th ECMC, we are pleased to announce the launch of a Special Issue in Pharmaceuticals to collect the most interesting contributions of this 9th ECMC, which has been hosted on the online platform sciforum.net throughout the month of November 2023. We have received a large number of outstanding contributions covering a wide variety of topics within the medicinal chemistry discipline. We invite authors to contribute extended versions of the work presented at the conference in the form of full research articles describing their original experimental results.

Authors are encouraged to use the Microsoft Word template or LaTeX template, provided by Pharmaceuticals, to prepare their manuscripts (see Instructions for Authors). All manuscripts will undergo peer review and, once accepted, will be published in this Special Issue. A 20% discount will be applied to the article processing charge.

Dr. Alfredo Berzal-Herranz
Dr. Maria Emília De Sousa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • small molecules as drug candidates
  • biomolecules, natural products, phages, and cells as therapeutic tools
  • biological targets and biomarkers
  • radiopharmaceutical sciences, radiochemistry, (hybrid) imaging, and nuclear medicine
  • pharmacokinetics and pharmacodynamics
  • pharmaceutical preparations and drug delivery

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 923 KiB  
Article
Development of New Drugs to Treat Tuberculosis Based on the Dinitrobenzamide Scaffold
by Tiago Delgado, João P. Pais, David Pires, Filipe G. A. Estrada, Rita C. Guedes, Elsa Anes and Luis Constantino
Pharmaceuticals 2024, 17(5), 559; https://doi.org/10.3390/ph17050559 (registering DOI) - 27 Apr 2024
Viewed by 103
Abstract
Tuberculosis (TB) continues to be a major global health challenge and a leading cause of death from infectious diseases. Inspired by the results from a previous work by our group on antimycobacterial N-alkylnitrobenzamides, which are structurally related to the nitrobenzamide family of [...] Read more.
Tuberculosis (TB) continues to be a major global health challenge and a leading cause of death from infectious diseases. Inspired by the results from a previous work by our group on antimycobacterial N-alkylnitrobenzamides, which are structurally related to the nitrobenzamide family of decaprenylphosphoryl-β-d-ribose oxidase (DprE1) inhibitors, the present study explored a broad array of substituted benzamides. We particularly focused on previously unexplored 3,5-dinitrobenzamide derivatives. Starting with 3,5-dinitrobenzoic acid, we synthesized a diverse library of amides, incorporating both linear and cyclic amine moieties and also assessed the impact of terminal aromatic groups connected through ether, ester, or amide bonds on the bioactivity of the compounds. The synthesis primarily utilized nucleophilic addition/elimination, SN2, and Mitsunobu reactions. The activity was impacted mainly by two structural features, the addition of an aromatic moiety as a terminal group and the type of linker. The most interesting compounds (c2, d1, and d2, MIC = 0.031 μg/mL) exhibited activities against Mycobacterium Tuberculosis (Mtb) H37Rv comparable to isoniazid. Complementary computational studies helped elucidate potential interactions with DprE1, enhancing our understanding of the molecular basis of their action. Our findings suggest that the most active compounds provide a promising foundation for the continued development of new antimycobacterial agents. Full article
(This article belongs to the Special Issue Selected Papers from the 9th International Electronic Conference on Medicinal Chemistry (ECMC2023))
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop